{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"description":"The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.","groups":[{"description":"CC-5013 (lenalidomide) plus oral high-dose dexamethasone","id":"OG000","title":"CC-5013/Dex"},{"description":"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone","id":"OG001","title":"Placebo/Dex"}],"paramType":"NUMBER","populationDescription":"Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized. Results reported (Response) are numbers of subjects.","reportingStatus":"POSTED","timeFrame":"Up to Unblinding (07 Jun 2005)","title":"Myeloma Response","type":"SECONDARY","unitOfMeasure":"Participants"}